Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: GILD.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Gilead Sciences (GILD) Stock Forecast and AI Rating

Deep analysis published Sep 20 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$159

+6.0%+8.7% incl. dividends

2031

5-Year

NEUTRAL

$191

+27.1%+43.8% incl. dividends

Published batch insight

Biopharma Cash Engine Confronts Impending Regulatory Price Squeeze and Patent Cliffs

Sharp divergence defines the analytical outlook, contrasting transformative twice-yearly capsid prevention adoption against mandatory statutory Medicare pricing concessions. Entrenched virology cash generation comfortably absorbs recent multi-billion acquired research charges, yet looming exclusivity horizons and capital allocation discipline dictate whether long-term valuation multiples can expand sustainably.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), J.P. Morgan (Titan), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Michael Burry (Vulture), Elon Musk (Visionary), Machiavelli (Insider), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Gilead Sciences at publication: $14,379 in five years versus $13,892 for S&P 500 benchmark.

Gilead Sciences · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.5% net dividend yield for Gilead Sciences.

Figure: Five-year synthesized consensus value path for Gilead Sciences compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 150.11 USD1-year price return: +6.02%5-year price return: +27.09%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter / date	Target (USD)	Quarter return	Total return	Forecast rationale
Q118 Dec 2026	151.88	+1.18%	+1.18%	Third-quarter results reaffirm base virology acceleration as Yeztugo adoption expands. Investors look past transient acquisition accounting, though elevated Treasury yields and caution ahead of late-December anito-cel regulatory decisions temper broad valuation multiple expansion.
Q218 Mar 2027	154.55	+1.76%	+2.96%	Resolution of key regulatory binaries, including anito-cel and once-weekly oral lenacapavir reviews, supports constructive sentiment. Clean fourth-quarter earnings restore positive reported profitability, confirming resilient cash conversion despite ongoing launch commercialization costs.
Q318 Jun 2027	156.86	+1.49%	+4.49%	Commercial launch execution for once-weekly prevention demonstrates healthy volume growth across domestic channels. Resilient core treatment sales absorb legacy product attrition, while restrictive monetary policy across global central banks continues capping broader market multiples.
Q418 Sept 2027	159.15	+1.46%	+6.02%	Mid-year financial disclosures confirm underlying operating margin stability near forty percent. Solid free cash flow generation easily funds continuous quarterly dividend disbursements, though preliminary legislative rhetoric regarding drug price negotiations prompts modest sector hesitation.
Q518 Dec 2027	158.45	-0.44%	+5.55%	Market models begin discounting upcoming 2028 Medicare negotiated price resets on Biktarvy. Strong quarterly volume gains and initial Livdelzi contributions cushion sentiment, but valuation multiple compression moderates overall equity performance into year-end.
Q618 Mar 2028	160.32	+1.18%	+6.80%	Initial implementation of negotiated Medicare pricing introduces visible gross-to-net discount pressure across exposed domestic channels. However, accelerating global Yeztugo sales and clean full-year 2027 operating cash flow demonstrate durable franchise defense.
Q718 Jun 2028	163.17	+1.78%	+8.70%	Encouraging Phase 3 data for anito-cel in earlier multiple myeloma settings validates pipeline diversification. Surging prevention adoption offsets government pricing concessions, allowing operational cash flows to resume balance-sheet de-leveraging.
Q818 Sept 2028	164.87	+1.04%	+9.83%	Late-stage clinical trial progression for once-yearly injectable lenacapavir enhances long-term terminal value visibility. Operating margins remain resilient as manufacturing efficiencies take hold, easily absorbing commercial overhead and sustaining steady equity accumulation.
Q918 Dec 2028	166.75	+1.14%	+11.08%	Robust second-half cash conversion and disciplined capital allocation support another dividend increase alongside selective share repurchases. International commercial expansion for Yeztugo accelerates, reinforcing defensive institutional demand despite volatile broader equity trading.
Q1018 Mar 2029	169.70	+1.77%	+13.05%	Full-year 2028 financial reporting demonstrates that non-viral specialty products contribute expanding profit shares. Virology cash flows remain resilient against statutory pricing adjustments, supporting modest per-share earnings growth and steady valuation recovery.
Q1118 Jun 2029	172.67	+1.75%	+15.03%	Commercial rollout of next-generation combination therapies preserves high HIV market share against generic threats in older classes. Free cash flow margins remain elite near thirty percent, underwriting opportunistic buybacks across consolidating markets.
Q1218 Sept 2029	174.39	+1.00%	+16.18%	Solid oncology contributions from Trodelvy and advancing antibody-drug conjugate platforms offset routine volume decay in mature antiviral lines. Earnings compound predictably, though approaching loss-of-exclusivity horizons for legacy assets keeps valuation multiples tethered.
Q1318 Dec 2029	177.41	+1.73%	+18.19%	Anticipation of regulatory filings for once-yearly prevention regimens reinforces terminal confidence in virology leadership. High operating cash flow allows management to rebuild liquid reserves while retiring maturing corporate notes into year-end.
Q1418 Mar 2030	179.42	+1.13%	+19.52%	Full-year 2029 results confirm sustainable normalized free cash flow exceeding twelve billion dollars. Strong cash conversion and consistent shareholder distributions provide robust downside insulation as broader macroeconomic growth displays late-cycle cooling.
Q1518 Jun 2030	181.00	+0.88%	+20.58%	Global adoption of long-acting lenacapavir formulations reaches mature scale, successfully migrating patients off aging single-tablet regimens. Oncology revenues expand toward targeted run-rates, defending group operating profitability against persistent government reimbursement friction.
Q1618 Sept 2030	183.66	+1.47%	+22.35%	Terminal multiple discounting emerges as analysts evaluate patent settlement timelines for core therapies entering the five-year forecast horizon. High owner earnings yield and disciplined share retirements fully cushion equity prices against valuation contraction.
Q1718 Dec 2030	185.64	+1.08%	+23.67%	Year-end financial results highlight durable multi-therapeutic diversification spanning virology, liver disease, and hematology. Robust balance-sheet liquidity and conservative interest coverage support consistent per-share compounding despite mature industry valuation multiples.
Q1818 Mar 2031	187.70	+1.11%	+25.04%	Reporting of 2030 annual performance validates unencumbered cash generation and another progressive dividend hike. Stable prescription retention across commercial payer books demonstrates the enduring clinical stickiness of the underlying antiviral ecosystem.
Q1918 Jun 2031	189.03	+0.71%	+25.93%	International market penetration and pipeline milestone execution sustain predictable mid-single-digit top-line growth. Easing macroeconomic capital costs provides mild valuation support, balancing terminal multiple compression as generic settlement deadlines edge perceptibly closer.
Q2018 Sept 2031	190.77	+0.92%	+27.09%	The five-year strategic horizon concludes with the core franchise successfully bridged onto next-generation long-acting regimens. Total shareholder returns reflect steady cash compounding and capital return delivery rather than speculative multiple re-rating.

The fundamental investment case rests on the economic transition from daily antiretroviral treatment to an ultra-long-acting capsid inhibitor platform. Core virology generates over twelve billion dollars in recurring annual cash flow, funding substantial shareholder distributions and pipeline absorption. However, equity valuation sensitivity centers on the impending Inflation Reduction Act price negotiation for bictegravir starting in 2028 alongside outer-year patent expirations. While the market excessively discounted headline accounting losses stemming from acquired research charges, durable capital appreciation requires commercial prevention expansion and disciplined business development execution to outpace legislated reimbursement erosion across government channels.

Key insights

Commercial conversion toward twice-yearly prevention expands the total addressable prophylaxis market rather than merely cannibalizing existing daily oral regimens across commercial books.
Accounting charges from acquired in-process research mask underlying forty-percent operating margins, yet external pipeline acquisitions consume genuine balance-sheet liquidity and elevate integration risks.
Restrictive benchmark interest rates elevate equity hurdle rates, dictating that total shareholder returns depend upon cash compounding rather than terminal multiple expansion.

Deep Dive

Prevailing market sentiment anchors on Gilead's recent stock surge, treating flawless clinical efficacy for lenacapavir in prevention as guaranteed long-term growth. Meanwhile, generalist commentary remains unsettled by the headline second-quarter acquisition write-off, assuming upcoming Medicare price negotiations and looming patent horizons will inevitably impair earnings durability. Pricing models largely dismiss acquisition charges as one-off noise while treating terminal cash flows as static annuities.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The reports establish that the crowd underestimates underlying cash durability while overestimating near-term multiple expansion. The analytical edge centers on recognizing that the ten-billion-dollar GAAP loss was an accounting expensing of upfront acquisition research, not operating cash depletion; trailing free cash flow exceeds thirteen billion dollars. However, the crowd mistakenly treats twice-yearly prevention as an instant offset to 2028 Medicare price cuts on Biktarvy. True edge lies in modeling steady per-share cash compounding rather than speculative valuation multiple re-rating.

Repricing catalyst

The primary convergence catalyst is the regulatory review window spanning the late December 2026 anito-cel decision and the February 2027 PDUFA action for once-weekly oral lenacapavir. Tangible approval data, accompanied by fourth-quarter disclosures restoring positive GAAP earnings and quantifying paid commercial prescription adoption for Yeztugo, will compel institutional analysts to replace headline accounting skepticism with updated cash flow models reflecting sustainable core franchise compounding.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of restrictive interest rates and elevated sovereign bond yields presents a mixed setup. Inelastic biological demand for essential antivirals and robust free cash flow insulate operational earnings from economic deceleration, but benchmark yields near five percent elevate capital hurdle rates, capping equity valuation multiple expansion.

Published consensus context

Advisor disagreement

The sharpest analytical disagreement centers on terminal valuation and capital allocation efficacy. Bullish frameworks view recent multi-billion-dollar acquisition charges as benign accounting artifacts that secured high-growth oncology assets ahead of lenacapavir's commercial ascendancy. Conversely, skeptical frameworks argue that management repeatedly incinerates surplus virology cash on low-return external pipelines while ignoring inevitable 2028 Medicare price cuts and patent cliffs. Resolving this tension requires observing whether twice-yearly prevention adoption and anito-cel commercial revenues generate genuine operating margin expansion before statutory pricing discounts materialize.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Lenacapavir long-acting prevention commercial hegemony: Twice-yearly injectable lenacapavir transforms HIV prophylaxis by eliminating daily oral pill adherence friction following stellar efficacy in pivotal PURPOSE trials. Rapid commercial adoption expands the addressable prevention cohort into high-margin recurring territory. This clinical breakthrough establishes durable pricing power and long-term cash generation extending well beyond legacy tenofovir formulations. Expected impact: +22%.
Biktarvy cash engine patent settlement runway: Biktarvy retains domestic treatment dominance, commanding nearly half the HIV patient base with exceptional resistance barriers and high switching costs. Established legal settlements defer full generic entry until the mid-2030s. This unyielding commercial annuity delivers massive baseline cash flow that self-funds clinical pipeline development and corporate capital returns. Expected impact: +15%.
High-conversion free cash flow owner compounding: Minimal maintenance capital expenditure below two percent of revenue allows underlying operations to convert over twelve billion dollars into annual normalized free cash flow. This prolific cash generation supports steady dividend growth and opportunistic share repurchases, providing an enduring equity valuation floor and reliable per-share compounding through macroeconomic cycles. Expected impact: +11%.
Oncology and liver specialty franchise scaling: Trodelvy label expansion into first-line metastatic breast cancer alongside commercial launches of Livdelzi in primary biliary cholangitis establishes meaningful non-viral diversification. These high-margin specialty therapies leverage existing commercial infrastructure to accelerate operating leverage, progressively buffering terminal cash flows against eventual loss-of-exclusivity transitions in mature antivirals. Expected impact: +10%.

Top frictions and headwinds

Medicare drug price negotiation margin compression: Mandatory Medicare Part D price negotiations under the Inflation Reduction Act target top-selling blockbusters, with statutory maximum fair prices for Biktarvy scheduled for 2028 implementation. Enforced discounts and expanding rebate liabilities compress gross-to-net realizations on substantial domestic volume, imposing a permanent structural drag on core virology profit margins. Expected impact: -13%.
Impending mid-decade virology patent cliff discounting: Financial models progressively discount terminal valuation multiples as loss-of-exclusivity horizons for legacy antiretroviral components approach during the 2030s. While lifecycle migration strategies aim to transition patients to newer combinations, the sheer revenue magnitude of exposed franchises creates persistent multiple compression that caps equity appreciation despite solid near-term cash generation. Expected impact: -11%.
Aggressive external pipeline acquisition cash burn: Deploying over thirteen billion dollars into external clinical acquisitions creates acute headline accounting losses through acquired research expensing while depleting liquid reserves. Slower commercialization payback, trial attrition, or integration bottlenecks across acquired cell therapy and antibody-drug conjugate assets threaten return on invested capital and constrain near-term share repurchase flexibility. Expected impact: -9%.
Elevated cost of capital valuation headwind: The higher-for-longer interest rate environment with sovereign Treasury yields hovering near five percent increases corporate hurdle rates and widens equity discount rates. High risk-free yields diminish the relative yield appeal of defensive pharmaceutical dividends, compressing institutional price-to-earnings multiples and demanding that shareholder returns rely strictly on fundamental earnings growth. Expected impact: -8%.

Tail risks

Accelerated generic Biktarvy patent litigation breach: An unexpected federal court ruling invalidating bictegravir formulation patents prior to established settlement horizons would expose the core fourteen-billion-dollar franchise to premature generic erosion. Wiping out billions in high-margin operating cash flow before next-generation regimens fully migrate patients would force immediate dividend freezes, credit rating pressure, and severe institutional equity liquidation. Probability: +24%. Expected impact: -26%.
Catastrophic acquired oncology pipeline clinical write-downs: Confirmatory Phase 3 trial failures or severe toxicities across newly acquired antibody-drug conjugates or cell therapies by 2028 would dismantle non-HIV diversification. Significant clinical setbacks would mandate multi-billion-dollar intangible impairments, permanently destroying invested capital. Disillusioned investors would enforce a steep conglomerate discount, contracting forward price-to-earnings multiples to depressed historical troughs. Probability: +26%. Expected impact: -20%.

Tail opportunities

Once-yearly lenacapavir formulation regulatory triumph: Pivotal Phase 3 PURPOSE 365 trial readouts validating once-yearly intramuscular lenacapavir would revolutionize preventive healthcare by late 2028. Perfect viral protection combined with annual dosing would completely monopolize global prophylaxis and eliminate adherence dropouts. Peak sales could surpass seven billion dollars, driving substantial upward revisions to long-term earnings and expanding valuation multiples. Probability: +35%. Expected impact: +26%.
Anito-cel frontline multiple myeloma dominance: Pivotal trial data establishing superior complete response durability and zero delayed neurotoxicity for anito-cel could secure accelerated approval in second-line or frontline multiple myeloma by 2028. Displacing incumbent CAR-T therapies would transform cell therapy into a four-billion-dollar oncology cornerstone, vindicating recent acquisition capital deployment and driving significant institutional multiple re-rating. Probability: +32%. Expected impact: +20%.

What to monitor

Thesis watchpoints

-- Quarterly Yeztugo net sales exceeding three hundred million dollars by mid-2027 confirms accelerating commercial conversion and uncompromised pricing power.

Key insights

Core HIV revenue growth decelerating below four percent annually across consecutive quarters indicates severe pricing erosion or competitive share loss.
Acquired pipeline research impairments exceeding two billion dollars through 2028 signals chronic capital destruction and demands full valuation reassessment.

Company Financial Analysis

Gilead Sciences Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Gilead's headline earnings display a dramatic split between accounting figures and operational reality. For the second quarter of 2026, the company reported an eye-catching net loss of over ten billion dollars, yet this paper deficit was driven almost entirely by one-time charges for acquired research. In stark contrast, underlying business performance remained exceptionally strong. Base product revenue climbed ten percent year-over-year, propelled by twelve percent expansion in core HIV medicines and surging prevention demand. Trailing free cash flow exceeded thirteen billion dollars, demonstrating that the underlying cash spigot continues generating robust organic profits.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 29.4B	USD 8.5B	USD 9.5B
2024	USD 28.8B	USD 480M	USD 10.3B
2023	USD 27.1B	USD 5.7B	USD 7.4B
2022	USD 27.3B	USD 4.6B	USD 8.3B
2021	USD 27.3B	USD 6.2B	USD 10.8B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	18.1x	TTM	Native	USD / USD
2024	>100x	TTM	Native	USD / USD
2023	18.0x	TTM	Native	USD / USD
2022	23.6x	Annual	Native	USD / USD
2021	14.7x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Gilead commands extraordinary pricing power that keeps underlying profitability among the highest in global healthcare. Gross profit margins consistently hover near seventy-nine percent, sustained by monopolistic antiviral treatments and low manufacturing costs for core tablets. While reported operating margins experienced a temporary paper collapse due to mid-2026 acquisition write-offs, underlying non-GAAP operating margins remain formidable near forty-nine percent. Looking ahead, statutory Medicare price negotiation starting in 2028 will compress net realizations, but rapid adoption of premium preventive formulations should help preserve consolidated operating profitability above forty percent.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 11.7B	39.7%	28.9%
2024	USD 1.7B	5.8%	1.7%
2023	USD 7.6B	28.0%	20.9%
2022	USD 7.3B	26.9%	16.8%
2021	USD 9.9B	36.3%	22.8%

Balance sheet and leverage

AI Review

Gilead's balance sheet reflects substantial financial resilience tempered by recent acquisition spending. Liquid cash reserves contracted to approximately three billion dollars by mid-2026 after funding multi-billion-dollar upfront purchases. Gross debt stands near twenty-six billion dollars, yet debt obligations remain comfortably staggered across future years. The true anchor of balance-sheet safety is powerful cash conversion. Generating over twelve billion dollars in annual operating cash flow gives the company more than ten times interest coverage. This dependable cash generation allows management to comfortably service debt and support shareholder dividends without facing solvency risks.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 24.9B	USD 9.6B	USD 17.4B net debt	1.55x
2024	USD 26.7B	USD 11.6B	USD 16.7B net debt	1.60x
2023	USD 25B	USD 7.3B	USD 18.9B net debt	1.43x
2022	USD 25.2B	USD 6.4B	USD 19.8B net debt	1.29x
2021	USD 26.7B	USD 6.5B	USD 21.4B net debt	1.27x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management maintains an extraordinarily capital-efficient physical footprint, spending less than two percent of total revenue on property and equipment. Producing small-molecule pills and biologic therapies requires minimal heavy industrial machinery, freeing up operational cash for intellectual property reinvestment. However, true investment intensity happens through external dealmaking. Management deployed over eleven billion dollars in cash during early 2026 to purchase biotechnology pipelines spanning cellular therapy and oncology. While physical capital needs remain light, commercial success now hinges upon turning these costly acquired scientific programs into profitable approved drugs.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 563M	USD 5.8B
2024	USD 523M	USD 5.9B
2023	USD 585M	USD 5.7B
2022	USD 728M	USD 5B
2021	USD 579M	USD 4.6B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	65	+7.8%	Not available	ORIGINAL
5Y	NEUTRAL	74	+42.4%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	144.11	151.29	156.11	14
+6M	March 18, 2027	139.78	153.92	160.8	14
+9M	June 18, 2027	132.79	155.75	167.23	14
+1Y	September 18, 2027	135.45	157.88	172.25	14
+15M	December 18, 2027	130.03	157.43	175.69	14
+18M	March 18, 2028	126.13	159.54	180.96	14
+21M	June 18, 2028	127.39	162.29	186.39	14
+2Y	September 18, 2028	122.3	163.72	190.12	14
+27M	December 18, 2028	119.85	165.67	195.82	14
+30M	March 18, 2029	116.25	168.19	199.74	14
+33M	June 18, 2029	118.58	171.11	205.73	14
+3Y	September 18, 2029	113.84	172.44	207.79	14
+39M	December 18, 2029	111.56	175.48	214.02	14
+42M	March 18, 2030	108.21	177.3	220.44	14
+45M	June 18, 2030	109.3	179.32	224.85	14
+4Y	September 18, 2030	106.02	181.61	224.92	14
+51M	December 18, 2030	103.9	183.57	229.42	14
+54M	March 18, 2031	104.93	185.9	236.23	14
+57M	June 18, 2031	102.84	187.41	240.95	14
+5Y	September 18, 2031	103.86	189.44	245.84	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The evidence across reports establishes a consistent fundamental pattern: headline GAAP net losses in mid-2026 reflect an accounting charge for acquired research rather than operational cash deterioration, with underlying base revenues expanding ten percent and generating over twelve billion dollars in recurring free cash flow. Weighting prioritizes reports grounded in primary SEC filings, verified patent settlement schedules extending Biktarvy exclusivity to 2036, and CMS statutory pricing timelines. Lower weights are assigned to extreme contrarian cases projecting immediate collapse or unconstrained multiple expansion. While the bear case rightly highlights that acquired pipelines deplete liquidity and Medicare price negotiations will compress domestic margins by 2028, it overlooks proven patent duration and rapid twice-yearly prevention adoption. Conversely, peak-multiple bull cases disregard competitive five-percent Treasury yields. The relative weights reflect balanced per-share cash compounding, favoring rigorously evidenced analyses over speculative narratives.

AI RESEARCHER

13.00%Weight

Universal Investor AI

The Polymath

Opus 5

Demonstrating premier evidentiary rigor through primary SEC 10-Q citations, FDA approval milestones, and White House pricing pacts, this analysis delivers superior causal clarity. It meticulously dissects the acquired research expensing while modeling realistic long-term compounding across virology and oncology, justifying the highest relative weight in the consensus path.

AI RESEARCHER

12.00%Weight

Universal Investor AI

The Polymath

GPT-6 Astra

Anchored in verified primary SEC disclosures and official CMS regulatory determinations, this report provides exceptional evidentiary quality. It rigorously reconciles reported accounting losses with normalized cash flow while incorporating realistic margin friction from federal pricing negotiations and cost of capital benchmarks, justifying a leading weight in the overall synthesis.

AI RESEARCHER

10.00%Weight

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

This report provides outstanding forensic examination of balance-sheet liquidity, debt maturity schedules, and non-GAAP margin reconciliation. It accurately models the timing of oral lenacapavir catalysts alongside realistic regulatory price headwinds. Its high evidentiary grounding and balanced long-term return profile warrant a substantial conviction weight.

AI RESEARCHER

9.00%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Presenting thorough analysis of Biktarvy generic patent settlements extending to 2036 alongside verified Trodelvy first-line label expansions, this report establishes high evidentiary quality. It convincingly explains why underlying business acceleration easily absorbs transient accounting charges, warranting a high weight reflecting its balanced, evidence-backed operational optimism.

AI RESEARCHER

8.00%Weight

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

This perspective excels in contextualizing biopharmaceutical cash generation within restrictive macroeconomic tightening and sovereign yield competition. It recognizes that equity returns must stem from organic operational earnings compounding rather than terminal multiple expansion. Its sound macro transmission mechanisms justify an above-average weight despite lighter company-specific pipeline granular detail.

AI THINKER

7.00%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

This analysis demonstrates solid causal consistency, recognizing that trailing accounting losses reflect one-off transaction charges rather than operational decay. It correctly balances lenacapavir launch execution against upcoming Medicare price negotiations. However, the lack of granular primary filing receipts justifies a measured weight relative to more thoroughly documented peers.

AI RESEARCHER

7.00%Weight

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

This perspective offers valuable insights into global access voluntary licensing and diplomatic insulation from populist price controls. It correctly identifies how upfront M&A expensing distorts headline metrics while core revenues expand. The weight reflects this strong political and institutional analysis, balanced against somewhat optimistic oncology commercial assumptions.

AI THINKER

7.00%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Offering a disciplined owner-earnings framework, this analysis properly emphasizes capital-light economics and high cash conversion. It soundly identifies valuation risks at current trading multiples while acknowledging durable competitive moats. A solid weight is warranted, though slight repetition of generalized value tropes keeps it below primary filing-grounded reports.

AI RESEARCHER

6.00%Weight

Michael Burry AI

The Vulture

Gemini 3.8 Flash

This report provides a credible discipline check on valuation, highlighting how high benchmark Treasury yields compress pharmaceutical price-to-earnings multiples. It accurately models statutory pricing drag and acquisition integration costs, though it somewhat underestimates the margin durability and total addressable market expansion delivered by twice-yearly injectable prevention regimens.

AI RESEARCHER

6.00%Weight

Elon Musk AI

The Visionary

Gemini 3.8 Flash

This analysis astutely diagnoses management's persistent tendency to deplete operational cash through speculative oncology acquisitions. It balances this friction against lenacapavir's biological moat. While offering sharp causal mechanisms, its somewhat cynical narrative on corporate capital allocation is tempered by evidence of disciplined underlying free cash flow generation.

AI RESEARCHER

5.00%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

This assessment provides a healthy skepticism regarding margin of safety and liquidity depletion following aggressive M&A disbursements. However, its conservative assumption of owner earnings fails to fully credit rapid Yeztugo commercial adoption and proven legal patent insulation, justifying a modest weight that preserves its prudent cautionary signals.

AI RESEARCHER

4.00%Weight

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

This report provides strong enthusiasm for Yeztugo but incorporates overly aggressive multiple expansion assumptions that disregard the prevailing high interest-rate regime. While correctly identifying core virology durability, its terminal enterprise valuation expansion exceeds prudent risk boundaries. A moderate weight preserves its commercial insight without overcommitting to its exuberant trajectory.

AI THINKER

3.00%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

While providing a useful contrarian warning regarding Biktarvy patent expiry and historical oncology capital destruction, this report overstates structural operational decay. Projecting severe persistent negative equity returns ignores thirteen billion dollars in annual free cash flow and proven generic settlement protection extending into the 2030s, warranting a restricted weight.

AI RESEARCHER

3.00%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

While offering detailed pipeline progression scenarios across oncology and long-acting prevention, this report assumes an overly optimistic multiple re-rating and rapid earnings acceleration. It underestimates structural drag from statutory Medicare price negotiations and elevated cost of capital, warranting a low weight to avoid skewing the consensus trajectory upward.

Research Provenance

References & Context

This Gilead Sciences consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 125 deduplicated sources retained for this batch.

01CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs | CMScms.gov
02gild-20260630sec.gov
03GILEAD SCIENCES, INC. - Form 10-Q - FY2026sec.gov
04GILEAD SCIENCES, INC. - Form DEF 14A - FY2026sec.gov
05Lakefront Biotherapeutics NV - Form 6-K - FY2026sec.gov
06Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
07Savings from Most-Favored-Nation Drug Pricing Policy – The White Housewhitehouse.gov
08Gilead Sciences, Inc. - Gilead Sciences Announces Second Quarter 2026 Financial Resultsinvestors.gilead.com
09Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure | AJMCajmc.com
10Gilead raises full-year guidance on 8% Q2 sales growth, eyes three near-term regulatory approvalsallsci.com
11Gilead Wins FDA Nod for Bixlenvo, New HIV Pill | AskTraders.com %asktraders.com
12FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientscnbc.com
13Drug companies sign "Most Favored Nation" deals, then raise prices anywaydrugdiscoverytrends.com
14With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'fiercebiotech.com
159 pharma giants reach US drug price deals with Trump administrationfiercepharma.com

And 110 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.